1. Cardoso, F, Kyriakides, S, Ohno, S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1194–1220.
Google Scholar | Crossref | Medline2. National Comprehensive Cancer Network . Breast cancer (Version 1.202). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed 28 January 2021).
Google Scholar3. Patiniott, PS, Wong, GYM, Lam, YH, et al. Neoadjuvant chemotherapy rates for breast cancer in Australia— “are we there yet?” Ann Breast Surg 2019;3:9.
Google Scholar | Crossref4. Mougalian, SS, Soulos, PR, Killelea, BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 2015;121:2544–2552.
Google Scholar | Crossref | Medline5. Berry, DA, Cirrincione, C, Henderson, IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658–1667.
Google Scholar | Crossref | Medline | ISI6. Hamilton, E, Infante, JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev 2016;45:129–138.
Google Scholar | Crossref | Medline7. Spring, LM, Wander, SA, Zangardi, M, et al. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep 2019;21:25.
Google Scholar | Crossref | Medline8. Im, SA, Lu, YS, Bardia, A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:307–316.
Google Scholar | Crossref | Medline9. Sledge, GW, Toi, M, Neven, P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 2019;6:116–124.
Google Scholar | Crossref10. Rugo, HS, Finn, RS, Diéras, V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 2019;174:719–729.
Google Scholar | Crossref | Medline11. Hurvitz, SA, Martin, M, Press, MF, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+/HER2- breast cancer. Clin Cancer Res 2020;26:566–580.
Google Scholar | Crossref | Medline12. Johnston, S, Puhalla, S, Wheatley, D, et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol 2019;37:178–189.
Google Scholar | Crossref | Medline13. Ma, CX, Gao, F, Luo, J, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res 2017;23:4055–4065.
Google Scholar | Crossref | Medline14. Curigliano, G, Pardo, PG, Meric-Bernstam, F, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast 2016;28:191–198.
Google Scholar | Crossref | Medline | ISI15. Gu, Y-L, Pan, S-M, Ren, J, et al. Role of magnetic resonance imaging in detection of pathologic complete remission in breast cancer patients treated with neoadjuvant chemotherapy: a meta-analysis. Clin Breast Cancer 2017;17:245–255.
Google Scholar | Crossref | Medline16. Scheel, JR, Kim, E, Partridge, SC, et al. MRI, clinical examination, and mammography for preoperative assesment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer: ACRIN 6657 trial. AJR Am J Roentgenol 2018;210:1376–1385.
Google Scholar | Crossref | Medline17. Marinovich, ML, Houssami, N, Macaskill, P, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 2013;105:321–333.
Google Scholar | Crossref | Medline18. American College of Radiology . ACR practice parameters for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast, revised 2018. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mr-contrast-breast.pdf?la=en (accessed 28 January 2021).
Google Scholar19. Sardanelli, F, Boetes, C, Borisch, B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 2010;46:1296–1316.
Google Scholar | Crossref | Medline | ISI20. Mann, RM, Balleyguier, C, Baltzer, PA, et al. Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 2015;2:3669–3678.
Google Scholar | Crossref21. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
Google Scholar | Crossref | Medline | ISI22. Union for International Cancer Control . TNM classification of malignant tumours. 8th ed. Hoboken, NJ: Wiley-Blackwell, 2017.
Google Scholar23. WHO Classification of Tumours Editorial Board . Breast tumours: WHO classification of tumours. 5th ed, Volume 2. IARC Press, 2019.
Google Scholar24. Tuominen, VJ, Ruotoistenmäki, S, Viitanen, A, et al. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010;12:R56.
Google Scholar | Crossref | Medline | ISI25. Wolff, AC, Hammond, MEH, Allison, KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018;36:2105–2122.
Google Scholar | Crossref | Medline26. Cheng, Q, Huang, J, Liang, J, et al. The diagnostic performance of DCE-MRI in evaluating the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Front Oncol 2020;10:93.
Google Scholar | Crossref | Medline27. Prat, A, Saura, C, Pascual, T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2020;21:33–43.
Google Scholar | Crossref | Medline28. Ko, ES, Han, B, Kim, RB, et al. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ann Surg Oncol 2013;20:2562–2568.
Google Scholar | Crossref | Medline29. Fukuda, T, Horii, R, Gomi, N, et al. Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype. SpringerPlus 2016;5:1–9.
Google Scholar | Crossref | Medline